Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1M8GC
|
|||
| Drug Name |
PRO 140
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Phase 2/3 | [1] | |
| Company |
CytoDyn
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 5 (CCR5) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Endocytosis | ||||
| Toxoplasmosis | ||||
| Viral carcinogenesis | ||||
| NetPath Pathway | TSLP Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| Reactome | Binding and entry of HIV virion | |||
| Chemokine receptors bind chemokines | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| HIV Life Cycle | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03902522) PRO 140 in Treatment-Experienced HIV-1 Subjects. U.S. National Institutes of Health. | |||
| REF 2 | The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.